With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50982-12-2,Dichloro(cycloocta-1,5-diene)ruthenium(II),as a common compound, the synthetic route is as follows.
b) A brown suspension of RuCl2(1,5-cyclooctadiene) (560 mg; 2 mmol), 0.6 ml of 1,8-diazobicyclo[5.4.0]undec-7-ene (DBU) and 1.18 g of tricyclohexylphosphine in 60 ml of isopropanol was stirred at 80 C. for 2 hours. 60 ml of toluene was added to the resulting brick-red suspension and the mixture was stirred at 80 C. for a further 90 minutes and cooled to -10 C. After addition of 0.55 ml of trimethylsilylacetylene, 10 ml of 2 M HCl solution in diethyl ether were added and the mixture was subsequently stirred for 5 minutes. The mixture was warmed while stirring to 0 C. and stirred for 45 minutes. After evaporation at 0 C. in a high vacuum, the residue was stirred with cold MeOH. The resulting violet powder was washed with cold methanol and dried under reduced pressure. Yield 1.40 g (92%).
50982-12-2 Dichloro(cycloocta-1,5-diene)ruthenium(II) 11000435, aruthenium-catalysts compound, is more and more widely used in various.
Reference£º
Patent; Evonik Degussa GmbH; US2011/40099; (2011); A1;,
Highly efficient and robust molecular ruthenium catalysts for water oxidation
Catalysts | Special Issue : Ruthenium Catalysts – MDPI